Investor Relations

Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.

 

In addition to our HBV Assets, we are developing a pipeline of Oncology, Anti-viral and Metabolic Programs that leverage our expertise in RNA interference (RNAi) therapeutics and our Lipid Nanoparticle (LNP) technology.

View all »   RSSRecent Releases

Jul 19, 2016
Arbutus Reports Topline Results from TKM-PLK1 HCC Clinical Trial

Jul 18, 2016
Arbutus to Present Data on New LNP Formulations for Delivery of mRNA at the 2016 Controlled Release Society Conference


View all »Events & Presentations

Jul 17, 2016
2016 Controlled Release Society Conference

Jun 21, 2016
JMP Securities Healthcare Conference